Free Trial
NASDAQ:PULM

Pulmatrix Q1 2025 Earnings Report

Pulmatrix logo
$6.44 -0.07 (-1.08%)
Closing price 03:55 PM Eastern
Extended Trading
$6.41 -0.03 (-0.47%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulmatrix EPS Results

Actual EPS
-$0.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulmatrix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulmatrix Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Pulmatrix's Q1 2025 earnings is scheduled for Tuesday, August 12, 2025

Pulmatrix Earnings Headlines

Pulmatrix Inc.
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM) is a clinical‐stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life‐threatening respiratory diseases. Utilizing its proprietary iSPERSE® particle technology, Pulmatrix aims to improve drug delivery to the deep lung by producing fine, dispersible dry‐powder formulations. The company’s approach is designed to enhance local drug concentration in the lungs while minimizing systemic exposure, offering potential safety and efficacy advantages over traditional delivery methods.

The company’s lead programs include PUR1900, an inhaled formulation of treprostinil for the treatment of pulmonary arterial hypertension, and PUR0200, an inhaled formulation of opelconazole targeting serious fungal infections in patients with cystic fibrosis and bronchiectasis. Both candidates have advanced through early‐stage clinical trials, demonstrating favorable tolerability and pharmacokinetic profiles. Pulmatrix also maintains a preclinical pipeline addressing additional acute and chronic pulmonary indications, leveraging the versatility of its iSPERSE platform to explore novel therapeutic areas.

Founded in 2006 and headquartered in Cambridge, Massachusetts, Pulmatrix conducts its research and development activities primarily in the United States, with clinical trial sites spanning North America and Europe. The company collaborates with academic institutions, contract research organizations, and strategic industry partners to advance its inhaled product candidates through regulatory pathways. Pulmatrix’s work aims to address significant unmet medical needs in both common and orphan lung diseases, positioning the company to capture opportunities in global respiratory markets.

Pulmatrix is led by a management team with extensive experience in respiratory drug development, regulatory affairs, and commercial strategy. Chief Executive Officer Paul M. H. Lee, Ph.D., oversees the company’s strategic direction, supported by a leadership bench that includes experts in pharmaceutical engineering, clinical operations, and business development. Under their guidance, Pulmatrix continues to pursue key regulatory milestones, manufacturing scale‐up, and potential licensing or partnership arrangements to bring its inhaled therapies closer to patients in need.

View Pulmatrix Profile

More Earnings Resources from MarketBeat